Clinical Trials · NCT05816057
A Study of the Efficacy and Safety of Semaglutide Injection in the Treatment of Type 2 Diabetes Mellitus
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Hangzhou Jiuyuan Gene Engineering Co. Ltd.,
- Enrollment
- 476
- Start date
- Jul 2022
- Locations
- 35 sites, China
- Primary endpoint
- The observed mean change in Glycosylated Haemoglobin A1c (HbA1c) values from baseline after 32 weeks of treatment.